Sign in Subscribe

Archive

A collection of 154 issues

Latest

CRC Research Finding

Skip to content The CRC Digest ▪ Methylation Biomarkers Show High Sensitivity for Colorectal Cancer Detection The Cologuard assay demonstrates 92% sensitivity for detecting colorectal cancer, both outperforming traditional screening methods through DNA methylation detection. (J Cancer Res Ther) This content is informational only and does not constitute medical advice. Always

CRC Research Update — June 04, 2026

Today's colorectal cancer research highlights

CRC Research Finding

Skip to content The CRC Digest ▪ Younger individuals with family history show increased advanced adenoma risk Study of 409 patients undergoing early screening colonoscopy due to first-degree relative with advanced polyps found increased prevalence of advanced adenomas in younger individuals, supporting current early screening guidelines. (Gastroenterology and Hepatology Advances) This

CRC Research Update — June 01, 2026

Today's colorectal cancer research highlights

BRAF V600E triplet regimen advances in phase 3 trial

Skip to content The CRC Digest BRAF V600E triplet regimen advances in phase 3 trial BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology) This content

CRC Research Finding

Skip to content The CRC Digest ▪ Screening test preferences vary by sociodemographic factors in underserved populations A survey of 1,014 adults aged 45-75 across community health centers found that preferences for stool test, blood test, and colonoscopy varied by sociodemographic factors and health beliefs, highlighting the need to understand

This Week in CRC Research — May 31, 2026

Weekly colorectal cancer research intelligence

ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases

Skip to content The CRC Digest ◆ TRIAL DATA ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.

Phase 2 study combines pembrolizumab with chemotherapy in MSS CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 study combines pembrolizumab with chemotherapy in MSS CRC — Clinical Colorectal Cancer A phase 2 study evaluated pembrolizumab (an immunotherapy) combined with capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer. This combination approach aims to overcome

AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer — Clinical Colorectal Cancer AZUR-4 is a phase 2, open-label, randomized study comparing neoadjuvant (before surgery) dostarlimab plus CAPEOX chemotherapy versus CAPEOX alone in previously untreated stage III or high-risk stage II mismatch